RT Journal Article SR Electronic T1 ROCK inhibitors for the treatment of ocular diseases JF British Journal of Ophthalmology JO Br J Ophthalmol FD BMJ Publishing Group Ltd. SP bjophthalmol-2017-310378 DO 10.1136/bjophthalmol-2017-310378 A1 Ramin Nourinia A1 Shintaro Nakao A1 Souska Zandi A1 Sare Safi A1 Ali Hafezi-Moghadam A1 Hamid Ahmadieh YR 2017 UL http://bjo.bmj.com/content/early/2017/08/09/bjophthalmol-2017-310378.abstract AB The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.